Source: Auxly.
  • Auxly (XLY) announced a $3.36 million private placement with institutional investors
  • Net proceeds will be used for working capital and general corporate purposes
  • The offering is expected to close during the week of February 13, 2023
  • Auxly is a leading Canadian cannabis consumer packaged goods company headquartered in Toronto
  • Auxly Cannabis Group (XLY) opened with a loss of 12.50 per cent, trading at $0.035 per share

Auxly (XLY) announced a $3.36 million private placement with institutional investors.

The investors have agreed to purchase 96,000,000 common shares and 96,000,000 share purchase warrants.

Each warrant enables the purchase of one XLY common share for $0.045 up to 60 months from the date of issuance.

Net proceeds will be used for working capital and general corporate purposes.

The offering is expected to close during the week of February 13, 2023.

All shares and warrants under the private placement will be offered exclusively to U.S. investors on the same basis pursuant to exemptions from registration requirements under the United States Securities Act of 1933.

Additionally, Auxly seeks to amend the terms of 27,381,500 share purchase warrants from a bought-deal offering completed on June 14, 2021. Changes include reducing the warrants’ exercise price from $0.38 to $0.045 per share and extending their expiry date from June 14, 2024 to June 14, 2026. The amendments are expected to take effect by late February or early March.

Auxly is a leading Canadian cannabis consumer packaged goods company headquartered in Toronto.

Auxly Cannabis Group (XLY) opened with a loss of 12.50 per cent, trading at $0.035 per share.


More From The Market Online
Cannabis Report across cannabis plants

StockTalk | Cannabis Report: Shake-ups

MediPharm Labs announced that chief executive officer, David Pidduck will step down from his role, effective January...

Buzz on the Bullboards: As Arctic tensions flare, investors eye three news‑making stocks

Global markets opened the week on edge as a fresh rift between Washington and key NATO...

MediPharm Labs announces CEO transition as David Pidduck steps down

MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition.
Cannabis leaves with Stock Talk and Cannabis Report labels

StockTalk | Cannabis Report: New digs

Cannabis e-commerce company Herbal Dispatch (CSE:HERB) grew sales by 38 per cent in 2025, marking its third-straight year...